Zacks Investment Research lowered shares of EnteroMedics (NASDAQ:RSLS) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning.
According to Zacks, “ReShape Lifesciences Inc. is a developer of invasive medical devices to treat obesity and metabolic diseases. The company’s portfolio includes vBloc System(R), ReShape(R) and Gastric Vest System (TM). ReShape Lifesciences Inc., formerly known as EnteroMedics Inc., is based in CA, United States. “
Separately, ValuEngine raised EnteroMedics from a strong sell rating to a sell rating in a research report on Friday, September 1st.
EnteroMedics (NASDAQ:RSLS) last announced its earnings results on Tuesday, November 14th. The medical device company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.77). The firm had revenue of $0.36 million during the quarter. EnteroMedics had a negative return on equity of 104.23% and a negative net margin of 4,509.61%. equities analysts anticipate that EnteroMedics will post -1.97 EPS for the current fiscal year.
EnteroMedics Company Profile
ReShape Lifesciences Inc, formerly EnteroMedics Inc, is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.
Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.